Missouri

Big River Mine Tailings Desloge (a/k/a St. Joe Minerals)—Desloge—(PB96–202379)

New York

Griffiss Air Force Base—Rome—(PB96–209861)

South Carolina

USMC Marine Corps Recruit Depot (a/k/a Parris Island Marine Corps Recruit Depot)—Parris Island—(PB96–214796)

Utah

Kennecott (North Zone)—Magna—(PB96–203260)

Virginia

Fort Eustis (US Army)—Newport News—(PB96–193362)

Petitioned Sites

Georgia

Basket Creek Surface Impoundment—Douglasville—(PB96–210125)
Basket Creek Drum Disposal—Douglasville—(PB96–210125)

Dated: January 17, 1997.

Georgi Jones,

Director, Office of Policy and External Affairs, Agency for Toxic Substances and Disease Registry.

[FR Doc. 97–1725 Filed 1–23–97; 8:45 am]

BILLING CODE 4163–70–P

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Grants for Education Programs in Occupational Safety and Health, Program Announcement 123: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Disease, Disability, and Injury Prevention and Control SEP: Grants for Education Programs in Occupational Safety and Health, Program Announcement 123.

Times and Dates: 3–5:30 p.m., 7:30–10 p.m., March 2, 1997. 7:30 a.m.–6 p.m., March 3, 1997. 7:30 a.m.–5 p.m., March 4, 1997.

Place: Commonwealth Hilton Hotel, I–75 and Turfway Road, Florence, Kentucky 45275.

Status: Closed.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 123.

The meeting will be closed to the public in accordance with provisions set forth in 5 U.S.C. Section 552b(c)(4) and (6), and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Contact Person for More Information: Bernadine Kuchinski, Ph.D., Office of Extramural Coordination and Special Projects, National Institute for Occupational Safety and Health, CDC, Mailstop D40, Atlanta, Georgia 30333, telephone 404/639–3342.

Dated: January 17, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–1726 Filed 1–23–97; 8:45 am]

BILLING CODE 4163–19–P

Food and Drug Administration

[Docket No. 96N–0287]

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information regarding investigational new drug application (IND) regulations has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. This document announces the OMB approval number.

FOR FURTHER INFORMATION CONTACT: Charity B. Smith, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1686.

SUPPLEMENTARY INFORMATION: In the Federal Register of October 31, 1996 (61 FR 56240), the agency announced that the proposed collection of information on IND regulations (21 CFR part 312) had been submitted to OMB for review and clearance. In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520), OMB has approved the information collection and assigned OMB control number 0910–0014. The approval expires on December 31, 1999. Under 5 CFR 1320.5(b), an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection displays a valid control number.

Dated: January 16, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–1786 Filed 1–23–97; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–253V]

Cigarettes and Smokeless Tobacco; Notice of Public Video Conference

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public video conference.

SUMMARY: The Food and Drug Administration (FDA) is announcing that it is sponsoring a national video conference to promote understanding of, and to encourage compliance with, FDA's regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents. The video conference will focus on those provisions of the final rule that take effect on February 28, 1997, when retailers will be prohibited from selling cigarettes, cigarette tobacco, or smokeless tobacco to persons under the age of 18, and will be required to check the photographic identification of persons under the age of 27 to verify their age. FDA officials will attend the conference, explain the new regulations, and be available to answer questions. The purpose of the national video conference is to advance the agency's mission to promote and protect the public health.

DATES: The video conference will be held on Tuesday, February 18, 1997, from 1 p.m. to 2:30 p.m., e.s.t. The deadline for registration is Tuesday, February 11, 1997. Persons will be registered in the order in which their call is received. Late registration will be accepted if space is available.

ADDRESSES: See Table 1 in the ''Supplementary Information'' section of this document.

FOR FURTHER INFORMATION CONTACT: See Table 1 in the ''Supplementary Information'' section of this document.

SUPPLEMENTARY INFORMATION: In the Federal Register of August 28, 1996 (61 FR 44396), FDA published a final rule to restrict the sale and distribution of cigarettes and smokeless tobacco in order to protect children and adolescents. These regulations will address the serious public health problem caused by cigarettes and smokeless tobacco products. They will

reduce children's and adolescents' easy access to cigarettes and smokeless tobacco and will significantly decrease the amount of positive imagery that makes these products so appealing to children.

Certain provisions in the rule have different effective dates. Starting February 28, 1997, the rule requires that retailers must not sell cigarettes, cigarette tobacco, or smokeless tobacco to any person under the age of 18, and retailers must check the photographic identification of every person under the age of 27 who wishes to buy such a product to verify that the purchaser is at least 18 years old. Starting August 28, 1997, the remaining provisions of the rule will become effective, except for the sponsorship provision, which will become effective starting August 28, 1998.

The video conference will focus on the provisions that will be effective starting February 28, 1997. The purpose of the conference is to educate retailers and the public about the new provisions and the agency's enforcement strategy. The conference format will include: Video segments providing background to the new regulations; filmed depictions of legal and illegal sales; live interviews with senior public officials; and a segment during which FDA officials responsible for implementing the rule will take questions from persons attending in the studio and around the country.

Interested persons may attend the video conference on Tuesday, February 18, 1997, between 1 p.m. and 2:30 p.m. (e.s.t.), at the locations listed in Table 1.

There is no charge to attend the video conference; however, advance registration is required because seating is limited. The deadline for registering is Tuesday, February 11, 1997. Persons will be registered in the order in which their call is received. Registration will be accepted so long as space is available. Late registration will be accepted only if space is available. Persons interested in attending should telephone their name, organization, address, and telephone number to the FDA contact person listed in Table 1.

TABLE 1

Metropolitan Area	Conference Address	FDA Contact Person
Buffalo, NY	University Cinema, 4100 Maple Rd., Amherst, NY	Diana Monaco, 716–551–4461
Burlington, VT	Sheraton-Burlington, 870 Williston Rd., Burlington, VT	Paula Fairfield, 617–279–1675
Charleston, SC	Aviation Avenue Cinemas, 2390 West Aviation Ave., North Charleston, SC	Sheila Bayne Lisby, 404–347–4001
Charleston, WV	Kanawha Cinemas, 601 57th St., Charleston, WV	Ruth Weisheit, 216–273–1038
Cincinnati, OH	Showcase Cincinnati, 1701 Showcase Dr., Cincinnati, OH	Marilyn Zipkes, 513–684–3501, ext. 110
Dallas/Fort Worth, TX	United Artists Bedford 10, 2000 Forum Pkwy., Bedford, TX	Juan Tijerina, 210–229–4531, ext. 13
Denver, CO	Greenwood Plaza, 8141 East Arapahoe Rd., Englewood, CO	Virlie Walker, 303–236–3018
Indianapolis IN	United Artists Circle Center Theatre, 49 West Maryland St., Indianapolis, IN	Janet LeClair, 317–226–6500
Jackson, MS	Parkway Place 10, 1075 Parkway Blvd., Flowood, MS	Darlene Tollestrup, 504–589–2420, ext. 121
Kansas City, MO	Bannister Mall 5, 5600 East Bannister Rd., #268, Kansas City, MO	Tywanna Paul, 913–752–2141
Little Rock, AR	Park Plaza 7, 6320 ''C'' St., Little Rock, AR	Gilbert Meza, 602–379–4595
Minneapolis, MN	Woodbury Theatre, 1470 Queens Dr., Woodbury, MN	Steve Davis, 414–771–7167
New Orleans, LA	Kenner 8, 1000 West Esplanade Ave., Kenner, LA	Darlene Tollestrup, 504–589–2420
New York, NY	Criterion Center Theatre, 1514 Broadway, New York, NY	Herman Janiger, 718–965–5300, ext. 5754
Norfolk, VA	Movies at Kempsriver, 1220 Fordham Rd., Virginia Beach, VA	Leonard Geneva, 410–962–3731
Orlando, FL	Movies at Florida Mall, 1001 Florida Mall Ln., Orlando, FL	Lynne Isaacs, 407–648–6922, ext. 202
Philadelphia, PA	Riverview Plaza, 1400 South Delaware Ave., Philadelphia, PA	Theresa Holmes, 215–597–4390, ext. 4202

TABLE 1—Continued

Metropolitan Area	Conference Address	FDA Contact Person
Phoenix, AZ	United Artists Christown Mall, 1546 West Montebello, Phoenix, AZ	Gil Meza, 602–379–4595
Portland, OR	Westgate 5, 3950 SW. Cedar Hills Blvd., Beaverton, OR	Alan Bennett, 503–671–9332
Raleigh, NC	Mission Valley Cinemas, 2109 Advent Ferry Rd., Raleigh, NC	JoAnn Pittman, 404–347–4001, ext. 5340
Saint Louis, MO	Westport Cinema, 910 Westport Plaza St., Louis, MO	Mary-Margaret Richardson, 314–645–1167, ext. 123
Salt Lake City, UT	Broadway Center Cinema, 111 East Broadway, Salt Lake City, UT	Virlie Walker, 303–236–3018
San Diego, CA	United Artists Horton Plaza, 475 Horton Plaza, San Diego, CA	Rosario Vior, 714–798–7607
San Francisco, CA	UA Emery Bay 10, 6330 Christie Ave., Emeryville, CA	Janet McDonald, 510–337–6845
San Juan, PR	United Artists Cinema, 150 Laguna Garden Shopping Ctr., San Juan, PR	Ruth Marcano, 787–729–6842

Dated: January 17, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–1719 Filed 1–21–97; 3:06 pm]

BILLING CODE 4160–01–F

[Docket No. 96N–0061]

Gary D. Mays; Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) debarring Mr. Gary D. Mays, 5304 John Thomas Dr. NE., Albuquerque, NM 87111, for a period of 5 years from providing services in any capacity to a person that has an approved or pending drug product application including, but not limited to, a biological product license application or an establishment license application. FDA bases this order on a finding that Mr. Mays was convicted of conspiracy to commit a felony under Federal law for conduct relating to the regulation of a drug product under the act while he was employed as responsible head of El Paseo Plasma, Inc., located at 1595 El Paseo, Las Cruces, NM. After being given notice of his proposed debarment and opportunity to request a hearing, Mr. Mays has failed to request a hearing. Therefore, Mr. Mays has waived his opportunity for a hearing concerning this action.

EFFECTIVE DATE: January 24, 1997

ADDRESSES: Application for termination of debarment to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Gloria Hicks, Center for Biologics Evaluation and Research (HFM–630), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–3074.

SUPPLEMENTARY INFORMATION:

I. Background

On December 14, 1989, the United States District Court for the District of New Mexico accepted a plea of guilty and entered judgment against Mr. Gary D. Mays for one count of a conspiracy to provide false statements in a matter within the jurisdiction of a Federal agency, a Federal felony offense under 18 U.S.C. 371. The basis for this conviction was Mr. Mays' act of falsification of whole blood logs, donor record files, quality control logs, destruction logs, records concerning the infusion of red blood cells to the wrong donor, and concealing and covering up by false statements at least two incidents of misconnecting for infusion, but not infusing, one donor with the red blood cells of another donor.

In order for FDA to regulate the blood plasma supply adequately and effectively, FDA requires that blood plasma facilities maintain accurate and complete records containing information regarding whole blood logs, donor record files, quality control logs, and destruction logs. Such records are crucial for FDA to assure that plasma products are safe, pure, and potent, and that the health of donors is protected in order to assure a continued healthy donor population. Because of Mr. Mays' omissions and falsifications in such records, FDA was prevented from obtaining accurate and complete information necessary to regulate the human blood plasma supply, and, therefore, FDA's process for the regulation of drug products was undermined.

As a result of his conviction, FDA delivered a letter, dated December 5, 1994, to Mr. Mays which provided notice of FDA's proposal to debar him for a period of 5 years from providing services in any capacity to a person that has an approved or pending drug product application including, but not limited to, a biological product license application or an establishment license application, and offered him an opportunity for a hearing on the proposal in accordance with 21 U.S.C. 335a and 21 CFR part 12. FDA based the proposal on its finding under section 306(b)(2)(B)(i)(II) of the act (21 U.S.C. 335a(b)(2)(B)(i)(II)) that Mr. Mays was convicted of conspiracy to commit a felony under Federal law for conduct relating to the regulation of a drug product under the act. Mr. Mays did not request a hearing. His failure to request a hearing constitutes a waiver of his opportunity for a hearing and a waiver of any contentions concerning his debarment.

II. Findings and Order

Therefore, the Deputy Commissioner for Operations, under section 306(b) of the act, and under authority delegated